Arcus Biosciences Inc (RCUS)
Solvency ratios
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 2.37 | 2.05 | 1.89 | 1.54 | 1.24 |
Based on the solvency ratios provided for Arcus Biosciences Inc, we can observe the following trends over the past five years:
1. Debt-to-assets ratio: The company has consistently maintained a debt-to-assets ratio of 0.00 across all years, indicating that the company has not used debt to finance its assets and relies primarily on equity for its capital structure.
2. Debt-to-capital ratio: Similar to the debt-to-assets ratio, the debt-to-capital ratio has remained at 0.00 for each year, reaffirming the company's reliance on equity as the primary source of capital.
3. Debt-to-equity ratio: The debt-to-equity ratio also remains at 0.00 for all years, indicating that the company has not utilized debt financing in relation to its equity position.
4. Financial leverage ratio: The financial leverage ratio, which measures the proportion of a company's assets that are financed by debt, has shown an increasing trend over the years, rising from 1.24 in 2019 to 2.37 in 2023. This suggests that the company has been gradually increasing its debt financing relative to its equity position.
Overall, Arcus Biosciences Inc has demonstrated a strong solvency position with minimal reliance on debt for its capital structure. However, the increasing trend in the financial leverage ratio warrants further monitoring to assess the impact on the company's financial risk and stability in the future.
Coverage ratios
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Interest coverage | -170.00 | -140.00 | 207.69 | — | — |
Unfortunately, without the specific interest expense data for Arcus Biosciences Inc provided in the table, it is not possible to calculate the interest coverage ratio for the years specified. The interest coverage ratio is a measure of a company's ability to meet its interest obligations on outstanding debt. It is calculated by dividing the earnings before interest and taxes (EBIT) by the interest expense. A higher interest coverage ratio indicates a company is more capable of meeting its interest payments.
To perform a thorough analysis of Arcus Biosciences Inc's interest coverage, it would be necessary to have access to the relevant financial data, specifically EBIT and interest expense figures for the years in question. Without this information, it is not feasible to provide a detailed assessment of the company's ability to cover its interest payments over the specified period.